Copanlisib (BAY80-6946)
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Conditions
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Trial Timeline
Jul 1, 2022 → Aug 31, 2024
NCT ID
NCT05217914About Copanlisib (BAY80-6946)
Copanlisib (BAY80-6946) is a pre-clinical stage product being developed by Bayer for Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05217914. Target conditions include Relapsed or Refractory Indolent Non-Hodgkin Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05217914 | Pre-clinical | Completed |
| NCT02455297 | Phase 2 | Terminated |
| NCT02342665 | Phase 1/2 | Completed |
| NCT02155582 | Phase 1 | Completed |
| NCT02119221 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma